CN114344551A

CN114344551A - Liquid embolism composition and application thereof, medical intervention apparatus and intervention treatment medicine

Info

Publication number: CN114344551A
Application number: CN202111677768.9A
Authority: CN
Inventors: 张国艺; 郭远益; 张朔; 虞鹏; 王亦群
Original assignee: Shenhong Medical Technology Shanghai Co ltd
Current assignee: Microport Neurotech Shanghai Co Ltd
Priority date: 2021-12-31
Filing date: 2021-12-31
Publication date: 2022-04-15
Anticipated expiration: 2041-12-31
Also published as: CN114344551B; WO2023125036A1

Abstract

The invention relates to a liquid embolism composition and application thereof, a medical intervention instrument and an intervention treatment drug. The liquid embolism composition is a dispersed mixed solution, the dispersed mixed solution comprises a continuous-phase dispersant solution and developable solid particles dispersed in the dispersant solution in a dispersed state, the developable solid particles are provided with holes for the dispersant solution to enter, and the dispersant solution contained in the holes and the dispersant solution outside the developable solid particles form a continuous phase. Thus, the loss of the developer caused by the rapid diffusion of the solvent can be reduced, and the developer is effectively solidified by the polymer, thereby ensuring the developing and plugging properties of the liquid plugging composition.

Description

Liquid embolism composition and application thereof, medical intervention apparatus and intervention treatment medicine

Technical Field

The invention relates to the technical field of medical instruments, in particular to a liquid embolism composition and application thereof, a medical interventional instrument and an interventional treatment drug.

Background

The interventional embolization technology is widely applied to clinical treatment of abnormal vascular lesions such as arteriovenous malformation (AVM) and arteriovenous fistula (DVF). The interventional embolization agent is a reagent required by interventional embolization technology, is a reagent with the function of embolizing tumor blood vessels, can form embolization in the lumen of the tumor blood vessels to further block the lumen of the blood vessels, and finally achieves the purpose of tumor ischemia and necrosis.

Currently, the types of interventional embolization agents are very diverse, and the classification according to the state includes two major types, solid embolization agents and liquid embolization agents. The embolization process of the solid embolization agent is relatively simple, but a large-diameter microcatheter is needed, so that the embolization agent cannot enter a focus part close to AVM and the like to perform more accurate embolization, and the problem of recanalization of blood vessels is easy to occur after particle embolization. Therefore, solid embolization materials are mostly used for preoperative embolization, and the requirement of curative embolization is difficult to meet.

Compared with a solid embolic agent, the liquid embolic agent has stronger fluidity, can be directly injected into tumor tissues and uniformly filled with lesion blood vessels through a thinner microcatheter, is completely suitable for tumors with different sizes and various shapes, and does not leave any gap between the tumor tissues and embolic materials, so that the blood vessels are blocked, the blood vessel recanalization possibility is reduced, and accurate and permanent embolization is realized.

The liquid embolic agents which are widely used clinically at present comprise two main types of adhesive liquid embolic agents and non-adhesive liquid embolic agents. The Onyx liquid embolic agent is a suspension formed by mixing ethylene vinyl alcohol copolymer, dimethyl sulfoxide (DMSO for short) and micron-sized tantalum powder according to a certain proportion, is a novel intravascular non-adhesive liquid embolic agent, and is also one of the most common non-adhesive liquid embolic agents. The operating principle of the Onyx liquid embolic agent is that the ethylene vinyl alcohol copolymer is water-insoluble but soluble in dimethyl sulfoxide, the nano-grade tantalum powder is used as a developer, when the liquid embolic agent is contacted with aqueous solution (such as blood for example), the dimethyl sulfoxide is quickly scattered into the aqueous solution, and the ethylene vinyl alcohol copolymer is precipitated into solid to play an embolizing role, for example, the ethylene vinyl alcohol copolymer can plug vascular ducts of focuses such as intracranial and the like, thereby achieving the purpose of blocking blood flow. The developer micron-sized tantalum powder can be developed under X-rays, and then is obtained by developing images, so that treatment and diagnosis of diseases are facilitated.

The liquid embolic agent taking the metal tantalum powder insoluble in the solvent as the developer is found in the postoperative follow-up, the developer is settled in the pushing process of the operation, and then remains in the human body, and the problem of metal artifact interference exists in the subsequent radiography. Therefore, it is an urgent problem to simultaneously reduce the developer residue and ensure the development and plugging performance of the plugging agent.

Disclosure of Invention

Based on this, there is a need for a liquid embolizing composition that can simultaneously reduce the residue of a developing agent and ensure the developing and embolizing properties, and applications thereof, a medical interventional instrument, and an interventional treatment drug.

The invention is realized by the following technical scheme.

In one aspect of the present invention, a liquid embolic composition is a dispersion mixed solution, the dispersion mixed solution includes a dispersant solution in a continuous phase and developable solid particles dispersed in the dispersant solution in a dispersion state, the developable solid particles have holes into which the dispersant solution can enter, and the dispersant solution contained in the holes and the dispersant solution outside the developable solid particles form a continuous phase.

In some of these embodiments, the dispersant solution includes a solvent and a polymer.

In some embodiments, the amount of the developable solid particles, the polymer, and the solvent in the dispersion mixture is 10% to 50%, 2% to 20%, and 50% to 78%, respectively.

In some of these embodiments, after the liquid embolization composition is solidified, the dispersant solution phase separates into a polymer phase and a solvent phase, the solvent phase diffuses into the liquid phase of the solidification environment, the polymer phase and the developable solid particles form embolization groups having the polymer as a continuous phase and the developable solid particles as a dispersed phase, the embolization groups being at least a portion of the polymer and the developable solid particles forming an interpenetrating network structure.

In some of these embodiments, the shape of the liquid embolic composition after curing can vary with the shape of the site being tamponaded.

In some of these embodiments, the porous particles on the surface of the developable solid particles are hollow particles, the surface of the hollow particles having porous pores; and/or

At least one of the holes on the surface of the developable solid particle is a through hole.

In some of these embodiments, the particle size of the developable solid particles is 0.1 μm to 200 μm;

and/or the wall thickness of the developable solid particles is 10 nm-10 μm.

In some of these embodiments, the interior and the surface of the developable solid particles have porous pores, wherein at least some of the pores are through-holes.

In some embodiments, the material of the developable solid particles is a metal or an alloy formed by the developable metal, or a metal compound formed by the developable metal.

In another aspect of the present invention, there is provided a method for preparing a liquid embolic composition, comprising the steps of:

the components of the liquid embolic composition of any of the above are mixed uniformly.

In another aspect of the present invention, there is provided a use of the liquid embolic composition of any of the above in the manufacture of a medical interventional device or an interventional treatment drug.

In another aspect of the present invention, there is provided a medical intervention device comprising a device body and an agent disposed in the device body, wherein the agent comprises the liquid embolic composition according to any of the above aspects.

In another aspect of the invention, there is provided an interventional procedure comprising a liquid embolic composition as defined in any of the above.

The liquid embolizing composition is a dispersion mixture in an uncured state, wherein the developable solid particles have pores for the dispersant solution to enter, the dispersant solution can penetrate into the pores, the dispersant solution contained in the pores forms a continuous phase with the dispersant solution outside the developable solid particles, so that the developable solid particles can be used as a tiny container for containing the dispersant solution, and the developable solid particles can play a 'storage tank' effect. The solvent in the storage tank has a slower diffusion rate than the solvent outside the storage tank, so that the diffusion time of the solvent is prolonged, and the slow release effect of the solvent is achieved. And with the dispersion of the solvent, the solvent outside the developable solid particles can be rapidly diffused, the polymer in the dispersant solution is rapidly precipitated and solidified, a small amount of solvent in the holes of the developable solid particles can be slowly diffused to form the gradient diffusion of the solvent, and finally the polymer in the holes forms solid plugs after being completely precipitated and solidified. Thus, the loss of the developer caused by the rapid diffusion of the solvent can be reduced, and the developer is effectively solidified by the polymer, thereby ensuring the developing and plugging properties of the liquid plugging composition. In addition, the gradient diffusion of a small amount of solvent neither influences the early-stage curing molding of embolic agent, can also reduce the joint strength of embolism group and microcatheter head end for the microcatheter can easily be pulled out, reduces the risk that postoperative extubation pulled the capillary network.

Drawings

FIG. 1 is a schematic illustration of a liquid embolic composition in an uncured state according to an embodiment of the present invention;

FIG. 2 is a schematic view of a liquid embolic composition in a solidified state according to an embodiment of the present invention.

Description of reference numerals:

11. a developable solid particle; 112. a hole; 12. a polymer.

Detailed Description

In order that the invention may be more fully understood, a more particular description of the invention will now be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. It is to be understood that these embodiments are provided so that this disclosure will be thorough and complete.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "a plurality" means at least two, e.g., two, three, etc., unless specifically limited otherwise.

One embodiment of the present invention provides a liquid embolic composition.

The liquid embolic composition is a dispersed mixed liquid before curing, i.e., in an uncured state. The dispersion mixed liquid comprises a dispersant solution in a continuous phase and developable solid particles dispersed in the dispersant solution in a dispersed state. In other words, the dispersant solution and the developable solid particles in the dispersion mixture form a "sea-island" structure in which "sea" is the dispersant solution and "islands" are the developable solid particles. Referring to fig. 1, in the dispersion mixture in an uncured state, the developable solid particles 11 are dispersed in a dispersant solution.

Further, the dispersant solution includes a polymer and a solvent; specifically, the dispersant solution is a polymer solution formed of a polymer and a solvent. In the specific example shown in fig. 1, in the dispersion mixed liquid in the uncured state, the polymer and the solvent form a polymer solution in which the developable solid particles 11 are dispersed well-miscible.

In some embodiments, the developable solid particles 11 have pores accessible to the dispersant solution, and the dispersant solution contained within the pores forms a continuous phase with the dispersant solution outside of the developable solid particles. The developed solid particles and the dispersant solution in the pores thus form again a "sea-island" like structure, i.e. the dispersant solution "sea water" can pass through the interior of the "islands" of developed solid particles.

It is understood that the developable solid particles therein act as a developer.

The liquid embolizing composition is a dispersion mixture in an uncured state, wherein the developable solid particles have pores for the dispersant solution to enter, the dispersant solution can penetrate into the pores, the dispersant solution contained in the pores forms a continuous phase with the dispersant solution outside the developable solid particles, so that the developable solid particles can be used as a tiny container for containing the dispersant solution, and the developable solid particles can play a 'storage tank' effect. The solvent in the storage tank has a slower diffusion rate than the solvent outside the storage tank, so that the diffusion time of the solvent is prolonged, and the slow release effect of the solvent is achieved. And with the dispersion of the solvent, the solvent outside the developable solid particles can be rapidly diffused, the polymer in the dispersant solution is rapidly precipitated and solidified, a small amount of solvent in the holes of the developable solid particles can be slowly diffused to form the gradient diffusion of the solvent, and finally the polymer in the holes forms solid plugs after being completely precipitated and solidified. Thus, the loss of the developer caused by the rapid diffusion of the solvent can be reduced, and the developer is effectively solidified by the polymer, thereby ensuring the developing and plugging properties of the liquid plugging composition. The slow release effect of a small amount of solvent does not influence the early-stage curing molding of the embolic agent, and the connection strength of an embolic mass and the head end of the micro catheter can be reduced, so that the micro catheter can be easily pulled out, and the safety of the operation is improved.

The polymer in the liquid embolic composition precipitates in the liquid phase of the solidification environment to form a physical solidification, forming an embolic mass.

In some embodiments, after the liquid embolic composition is cured, the dispersant solution phase separates into a polymer phase and a solvent phase. The solvent phase diffuses into the liquid phase of the solidification environment and the polymer phase and the developable solid particles form plug clusters with the polymer as the continuous phase and the developable solid particles as the dispersed phase. In other words, the polymer phase and the developable solid particles are in a "sea-island" structure with the polymer being the "sea" and the developable solid particles being the "islands". In this manner, the polymer precipitates to form a solid plug encapsulating the developer. And due to the existence of the holes of the developable solid particles, the formed plug groups are at least partially polymers and the developable solid particles form an interpenetrating network structure. Referring to fig. 2, at least a portion of polymer 12 is disposed through pores 112 of developable solid particles 12.

In the solid embolus, the interpenetrating network structure does not influence the embolism performance of the polymer and the development performance of the developable solid particles, and also provides a fixing effect for the developable solid particles, on one hand, the polymer and the solvent have good intersolubility, the sedimentation of the developable solid particles is reduced, on the other hand, the polymer can be rapidly settled along with the sedimentation of the polymer during solidification, and then the risk that the developable solid particles escape along with the diffusion of the solvent to cause the loss of the developer is reduced, so that the risk that the developable solid particles enter other non-target positions can be effectively reduced, and the problems of contrast artifacts, metal induction misjudgment and the like are avoided.

Further, the shape of the plug mass formed after the liquid embolic composition is cured can vary with the shape of the site to be plugged. For example, the liquid embolic composition can form appearance features with special sizes along with the change of curing environment, such as in narrow channels or complex multi-channel environment, and the liquid embolic composition can be dispersed into different channels along with the traction of the mobile phase to be cured to form embolic masses. In other words, the liquid embolic composition can change its cured shape with the shape of the site to be tamponaded, so that the cured shape of the liquid embolic composition matches the shape of the site to be tamponaded.

Further, the developable solid particles have a plurality of pores. In some embodiments, at least one of the holes is a through hole. The through holes are formed by communicating two ends of the holes distributed in the developable solid particles with the outside, and the holes penetrate through the inside of the developable solid particles from one end and penetrate through the other end. The through holes can have a larger storage space, enable a smaller average density of the developable solid particles, and also enable more efficient interpenetration fixation of the polymer therein. Preferably, at least part of the polymer is disposed through the through-holes of the developable solid particles.

Further, at least part of the chain segments of the polymer are arranged in the through holes of the developable solid particles in a penetrating way.

It is understood that at least a portion of the chain segments of the polymer are disposed through the through holes of the developable solid particles, and may be in one of the following states: partial chain segments of the polymer penetrate through the through holes of the developable solid particles, and partial chain segments are exposed outside the developable solid particles. Alternatively, the entire polymer is disposed through the through-holes of the developable solid particles. The penetration distribution in different states can be obtained according to the molecular size of the polymer and the size of the through holes. Generally, due to the large molecular weight of the polymer, only a portion of the segment of the polymer penetrates and is distributed in the through hole of the developable solid particle, and the segment is exposed outside the developable solid particle.

In some embodiments, the dispersion mixture contains 2% to 20% by mass of the polymer, 10% to 50% by mass of the developable solid particles, and 50% to 78% by mass of the solvent. Within the specific ratio range, the dispersion uniformity of the dispersion liquid mixture is good.

Further, in the dispersion mixture, the polymer is 2 to 20% by mass, preferably 2 to 10% by mass; the developable solid particles are 10-50%, preferably 20-40%, and the solvent is 50-78%, preferably 60-70%. The ratio of polymer, solvent and developable solid particles is controlled in such a way that the dispersant solution has a concentration which enables the dispersed phase to have better fluidity and also enables the developable solid particles to have better suspension.

In some of these embodiments, the developable solid particles are hollow particles having porous pores on the surface.

Further, the hollow structure of the developable solid particle communicates with at least part of the hole to form a through hole. Therefore, the polymer can penetrate and distribute in the through holes formed by the hollow structures of the developable solid particles and the holes on the surface, and more effective penetration and fixation are formed.

Further, the particle size of the developable solid particles is 0.1 μm to 200 μm. Preferably, the particle size of the developable solid particles is 0.5 μm to 50 μm.

Further, the wall thickness of the developable solid particles is 10nm to 10 μm.

When the developable solid particles are hollow particles, an appropriate average density can be obtained by optimizing the wall thickness of the hollow particles and the particle size of the microspheres, and the average density can enable the hollow particles to have better suspensibility in the liquid embolic composition, be easy to disperse and be difficult to settle.

In some of these embodiments, both the interior and the surface of the developable solid particles have pores, wherein at least a portion of the pores are through holes. Thus, the polymer can penetrate and distribute in the holes of the developable solid particles to form more effective penetration and fixation.

Further, the developable solid particles are microspheres. Further, the porosity of the developable solid particles is 10% to 70%.

Further, the developable solid particles contain a developable metal. In some of these embodiments, the developable metal is at least one of gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), tungsten (W), and barium (Ba). These metals have good visibility under X-rays. In some embodiments, the developable metal can also include at least one of a lanthanide, an actinide metal.

In some embodiments, the developable solid particles are made of a metal or an alloy of the above developable metal; alternatively, the material of the developable solid particles is a metal compound formed of a developable metal.

The metal is one of gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), tungsten (W), and barium (Ba).

The alloy is formed by at least two of gold (Au), silver (Ag), platinum (Pt), iridium (Ir), chromium (Cr), tantalum (Ta), bismuth (Bi), cobalt (Co), tungsten (W) and barium (Ba), namely the alloy metal.

The metal compound is a compound formed by a metal element and a non-metal element.

Further, the metal compound is at least one of a solvent-insoluble metal salt, a metal oxide, a metal carbide, and a metal nitride formed of a developable metal. For example, the metal compound material may be silver halide, bismuth oxide, tantalum carbide, barium sulfate, tungsten oxide, tantalum nitride, tantalum oxide, or the like.

It is understood that the developer may be one or more developable solid particles. When the developer contains a plurality of developable solid particles, the developer may be made of a metal material, an alloy material, a metal compound material, or at least two of the above materials.

In some of these embodiments, the weight average molecular weight of the polymer is from 1 to 40 ten thousand. Preferably, the weight average molecular weight of the polymer is 1 to 30 ten thousand. Further, the polymer is a hydrophobic polymer or an amphiphilic polymer.

Further, the molar content of the hydrophobic component of the polymer is more than 50%, preferably more than 60%. Wherein the hydrophilic component is a hydrophilic group contained in a side chain or a main chain of the polymer, and is a hydrophobic component otherwise. The higher the content of the hydrophobic component is, the shorter the polymer is precipitated in water, buffer solution or blood, the lower the solidification rate, and the solidification rate can be controlled by adjusting the proportion of the hydrophilic component and the hydrophobic component.

In some of these embodiments, the polymer is any one of a polyolefin, a polyolefinic alcohol, a polymethacrylate, a polyurethane, a polyester, a polyether, a polysiloxane, and a polyamide, or a copolymer of at least two thereof.

In some of these embodiments, the solvent is at least one of a biocompatible organic solvent, water, and a buffer. Further, the biocompatible organic solvent includes at least one of dimethyl sulfoxide, N-methylpyrrolidone (NMP), ethanol, and isopropanol. It is understood that the solvent may be selected according to the kind of the polymer, as long as it enables the polymer and the solvent to form a homogeneous system. Homogeneous system here means a homogeneous clear solution or a homogeneous suspension. Further, the solvent may be a good solvent for the above-mentioned polymer, i.e., the solvent and the polymer can form a uniform clear solution, or the solvent and the polymer can form a uniform system under specific conditions.

Further, the polymer is a hydrophobic polymer or an amphiphilic polymer, and the solvent is a biocompatible organic solvent.

The hollow microspheres can be prepared by a polymer template method. The polymer template method is to form a metal layer or a metal compound layer on the surface of a polymer microsphere by using the polymer microsphere as a template.

For example, the hollow microspheres are prepared as follows: firstly preparing polymer microspheres with a certain particle size by adopting methods such as emulsion polymerization or self-assembly and the like, and then depositing or modifying a metal compound on the surfaces of the polymer microspheres to form a metal layer, an alloy layer or a metal compound layer. And then eluting by using a specific solvent to remove the polymer microsphere body serving as the inner core, or removing the polymer microsphere body by calcining or other means at a specific temperature to obtain the hollow metal compound material microsphere. The hollow microspheres can also be obtained by using a solvent and calcining simultaneously, for example, eluting with the solvent and then removing the polymer microsphere body by calcining. Thus, the surface of the hollow microsphere is also formed into a porous structure. Wherein, the shell layer can form holes by controlling the molecular growth and accumulation process of the shell layer.

The polymer microspheres used therein can be obtained by direct commercial purchase, for example, polyethylene, polystyrene-divinylbenzene, etc.

Further, the developable solid particles having pores both inside and on the surface can be prepared by a high-temperature calcination or a hydrocracking method.

Another embodiment of the present invention also provides a method for preparing the liquid embolic composition, which comprises uniformly mixing the polymer, the solvent and other components to obtain an uncured dispersion mixture. And solidifying the dispersion mixed liquid to form the solid embolus.

Further, the mixing may be carried out by a conventional method such as stirring or ultrasonic, as long as the liquid embolic composition can be formed into a uniform system.

Further, the polymer and the solvent can be mixed by mechanical stirring and the like to form a polymer solution with a uniform phase, then the developer is added, and the polymer solution and the solvent are mixed by mechanical stirring and the like to form a uniform dispersion system.

Furthermore, in the step of forming a homogeneous phase polymer solution, the dissolution can be assisted by heating, cooling, physical dispersion, and the like.

The dispersed mixed liquid can be conveyed or pushed to water or blood, and the polymer in the liquid embolism composition precipitates out along with the diffusion of the solvent to form soft embolism groups, and the developer in the embolism groups ensures the good developing performance of the embolism groups.

The invention also provides application of the liquid embolism composition in preparation of a medical intervention device or an intervention treatment drug.

In another embodiment, the invention also provides a medical intervention device, a device body and an agent disposed in the device body, the agent comprising a liquid embolic composition as in any of the above.

In some of these embodiments, the instrument body is a catheter. Further, the inner diameter of the catheter is small, and is called a microcatheter. Typically, the microcatheter has an inner diameter of 0.007 to 0.013 inch.

In another embodiment, the present invention provides an interventional procedure comprising a liquid embolic composition according to any of the above aspects.

Further, the interventional therapy medicament may comprise, in addition to the liquid embolic composition as defined in any of the above, a drug or an active component of a drug as a therapeutic agent.

Further, the interventional therapy medicament may comprise other additives in addition to the liquid embolic composition according to any of the above.

The liquid embolic composition can be used in interventional therapy, such as in interventional hemostasis, vascular malformations, and malignancies, including but not limited to cerebral arteriovenous malformations (AVM), hematomas, and cerebral arteriovenous fistulas (DVF), in interventional embolization therapy of peripheral isovaricose veins, and in occlusion therapy of blood flow at tumors and the like.

The liquid embolic composition in its uncured state reaches the focal area by bolus injection through the microcatheter, contacts the blood stream, and begins to cure as the solvent diffuses. In blood flow, the polymer in the liquid embolism composition is slowly precipitated, separated and solidified to form an embolism cluster, thereby achieving the purposes of blocking a blood vessel passage and blocking blood flow; meanwhile, the therapeutic agent can effectively improve the treatment effect on other disease symptoms in the interventional therapy process or in the process of realizing curative embolism.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the patent of the invention is subject to the appended claims, and the description can be used for explaining the contents of the claims.

Claims

1. The liquid embolism composition is characterized in that the liquid embolism composition is a dispersion mixed solution when not solidified, the dispersion mixed solution comprises a continuous-phase dispersant solution and developable solid particles dispersed in the dispersant solution in a dispersion state, the developable solid particles are provided with holes for the dispersant solution to enter, and the dispersant solution contained in the holes and the dispersant solution outside the developable solid particles form a continuous phase.

2. The liquid embolic composition of claim 1, wherein the dispersant solution comprises a solvent and a polymer.

3. The liquid embolic composition of claim 2, wherein the developable solid particles are 10% to 50%, the polymer is 2% to 20%, and the solvent is 50% to 78% by mass in the dispersion mixture.

4. The liquid embolization composition of claim 1, wherein after the liquid embolization composition is solidified, the dispersant solution phase separates into a polymer phase and a solvent phase, the solvent phase diffuses into the liquid phase of the solidification environment, the polymer phase and the developable solid particles form embolization groups having the polymer as a continuous phase and the developable solid particles as a dispersed phase, the embolization groups being network structures at least a portion of which interpenetrate the developable solid particles.

5. The liquid embolization composition of claim 4, wherein the shape of the liquid embolization composition after curing varies with the shape of the site being plugged.

6. The liquid embolization composition of claim 1, wherein the developable solid particles are hollow particles having porous pores on the surface; and/or

7. The liquid embolic composition of claim 6, wherein the particle size of the developable solid particles is 0.1 μ ι η to 200 μ ι η;

and/or the wall thickness of the developable solid particles is 10 nm-10 μm.

8. The liquid embolization composition of claim 1, wherein the developable solid particle has porous pores both inside and on the surface, wherein at least some of the pores are through-pores.

9. The liquid embolic composition of any of claims 1 to 8, wherein the developable solid particles are made of a metal or alloy formed from a developable metal, or a metal compound formed from a developable metal.

10. Use of a liquid embolic composition according to any of claims 1 to 9 for the manufacture of a medical interventional device or an interventional therapy.

11. A medical intervention device comprising a device body and a liquid embolic composition according to any of claims 1 to 9 disposed within the device body.

12. An interventional procedure comprising a liquid embolic composition according to any of claims 1 to 9.